Most of the 17 products are targeted oncology drugs, and all of them are oncology or rare disease drugs with huge clinical demands. Most of them have been rapidly marketed through priority review or "two-application two-approval" policy, and after they are included in the medical insurance payment, payment pressure of patients will be further reduced.
According to statistical data, the 17 drugs have been reduced prices by 27%-74% after succeeding in the medical insurance access negotiations, wherein, Zykadia (ceritinib) will be reduced price by up to 74%. Refer to the attached table for the detailed prices.
II. Anticancer Drugs to be Further Reduced Prices after being Included in the Medical Insurance: A Comparison of Their Prices in China and outside China

|
赞可达 泰瑞沙 英立达 赛可瑞 达希纳 爱必妥 维全特 亿珂 索坦 维达莎 佐博伏 恩莱瑞 拜万戈 福可维 吉泰瑞 善龙 艾阳 |
Zykadia Tagrisso Inlyta Xalkori Tasigna Erbitux Votrient Imbruvica Sutent Vidaza Zelboraf Ninlaro Stivarga FOCUS V Gilotrif Sandostatin LAR Aiyang |
|
中标价格(元) 医保谈判(元) |
Bid winning price (RMB) Medical insurance negotiation price (RMB) |
I have obtained prices of the 17 drugs in China and outside China according to public data, with prices in China subject to bid winning prices in provinces of China and overseas prices subject to those in the U.S.
Bid winning prices in China are generally 30%-50% of prices of same specifications in the U.S. The drug prices will be further reduced after success of the medical insurance access negotiations, as proved by that the fact that the medical insurance negotiation prices are 47%-96% lower than the U.S. prices, which will significantly reduce payment pressure of patients. Refer to the following table for the details:
|
Trade name |
Specification |
U.S. (RMB) |
Bid winning price (RMB) |
Medical insurance price (RMB) |
Reduction of medical insurance negotiation price vs bid winning price |
Reduction of medical insurance negotiation price vs U.S. price |
|
Zykadia |
150mg |
749 |
749.00 |
198 |
74% |
74% |
|
Tagrisso |
80mg |
Read More
Related News
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ
PR Newswire July 29, 2025 Halozyme Announces Phase 2 Study in Advanced Pancreas Cancer Meets Key Endpoints
americanpharmaceuticalreview January 6, 2017 Janssen and Bristol-Myers Squibb to Evaluate DARZALEX® in Combination with OPDIVO®
americanpharmaceuticalreview January 6, 2017 You may like
Oncology
Vacuum suction cup hanger steel plate high temperature aluminum plate suction cup titanium plate and other metal plate suction cup under 30 tons
Lobaplatin Platinum-based anticancer drugs
Oncology
Tempered glass suction cup hanger, glass deep processing handling lifting suction cup, glass 90 degree flip suction crane
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Most popular
The Rise of Biosimilars: Regulatory Pathways and Market Outlook
Nurah Ekhlaque
Sep 19, 2025
Basic Concepts and Latest Trends in Radiation Biology: Emerging Insights and Future Directions
Sadia Ajmal
Sep 18, 2025
Convert secures €13.6m grant to develop targeted chemo for oxygen-deprived tumours
pharmafile
Mar 12, 2018
New Products MORE
中文站-新建产品-en
High Temperature Banana Oil Magnetic Coupling Pump Set for Diesel Fuel
test-Product Name1
![]()
Cell Culture Flask
![]()
Aseptic Transfer Cap
![]()
SUS Aseptic Welder
|










(All Rights Reserved)